Novel insights into capillary vessel basement membrane damage by snake venom hemorrhagic metalloproteinases: A biochemical and immunohistochemical study by Escalante Muñoz, Teresa et al.
Archives of Biochemistry and Biophysics 455 (2006) 144–153
www.elsevier.com/locate/yabbiNovel insights into capillary vessel basement membrane 
damage by snake venom hemorrhagic metalloproteinases: 
A biochemical and immunohistochemical study
Teresa Escalante a, John Shannon b, Ana M. Moura-da-Silva c, 
José María Gutiérrez a, Jay W. Fox b,¤
a Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica
b Department of Microbiology, Health Sciences Center, University of Virginia, Jordan Hall, P.O. Box 800734, Charlottesville, VA 22908-0734, USA
c Laboratorio de Imunopatologia, Instituto Butantan, Sao Paulo, Brazil
Received 9 August 2006, and in revised form 15 September 2006
Available online 6 October 2006
Abstract
The hemorrhagic activity characteristic of viperid snake envenomations is due to the action of venom metalloproteinases (SVMPs) on
the capillary vessel basement membrane (BM). This study compared the action of two SVMPs on BM in vitro (degradation of Matrigel)
and in vivo (immunohistochemical assessment of BM markers in mouse gastrocnemius muscle). SVMPs BaP1 (belonging to the P-I class)
and jararhagin (of the P-III class) had a similar proteolytic activity on azocasein and degraded Matrigel with a slightly diVerent cleavage
pattern, since BaP1 exerted a limited proteolysis of both laminin and nidogen, whereas jararhagin predominantly degraded nidogen. In
contrast with this pattern of limited proteolysis of BM proteins observed in vitro, immunohistochemical analysis of laminin, nidogen and
type IV collagen, as well as of the endothelial cell marker VEGFR-2, in the hemorrhagic areas in the muscle, revealed a pronounced
reduction in the immunostaining of these three BM components, associated with a loss of the endothelial cell marker. BM of muscle Wbers
was aVected to a lesser extent. In conclusion, in vitro results demonstrated that SVMPs induce a pattern of limited proteolysis on BM
components. The drastic loss of these antigens in aVected capillaries in vivo is likely to depend on the combination of limited proteolysis of
BM and the action of hemodynamic biophysical forces, previously shown to play a role in SVMP-induced capillary damage, which may
cause a mechanical disruption of BM structure.
© 2006 Elsevier Inc. All rights reserved.
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multiple deleterious eVects, including local and systemic
bleeding [1,2]. Hemorrhagic toxins of viperid venoms are
zinc-dependent metalloproteinases which, together with the
ADAMS (A Disintegrin And Metalloproteinase),1 comprise
the M12 reprolysin family of metalloproteinases [3].
Depending on their domain constitution, snake venom
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doi:10.1016/j.abb.2006.09.018metalloproteinases (SVMPs) are classiWed within four main
classes; the mature proteins of class P-I are composed of
the metalloproteinase domain, having a characteristic zinc-
binding motif [4]. The other classes (P-II to P-IV) present,
besides this catalytic domain, additional domains such as
disintegrin (or disintegrin-like), cysteine-rich and C-type
lectin-like domains, with additional variations within each
class [3]. Despite sharing a very similar zinc-binding motif,
not all SVMPs are able to induce hemorrhage; as a general
rule, P-III SVMPs, comprised of metalloproteinase, disinte-
grin-like and cysteine-rich domains, are more potent hem-
orrhagic components than P-I SVMPs [5].
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been investigated using various methodologies (for reviews
see References 6,7), although the precise molecular and cel-
lular events associated with microvessel disruption remain
largely unknown. Enzymatic hydrolysis of basement mem-
brane (BM) components has been proposed as a key event
in the onset of capillary vessel disruption [5,8]. In vitro,
SVMPs are able to digest the BM preparation Matrigel [9],
as well as puriWed BM components [9–14]. Most of these
analyses have been performed by observing the patterns of
hydrolysis in SDS–PAGE. However, the characterization
of the cleavage patterns on BM components of hemor-
rhagic and non-hemorrhagic SVMPs, as well as of SVMPs
of diVerent classes, has not been performed in detail, with
the exception of atrolysin e, a P-I SVMP from the venom
of the rattlesnake Crotalus atrox [5,11,12,15]. BM is a com-
plex extracellular matrix structure comprising several
major components, i.e. laminin, type IV collagen, nidogen/
entactin and the proteoglycan perlecan, in addition to a
number of minor components [16]. BM is a supramolecu-
lar lattice which, among other functions, provides mechan-
ical stability to the capillary vessel structure [16]. Hence,
SVMPs that have diVerent degradation patterns on BM
proteins are likely to aVect the mechanical stability of this
network to diVerent extents, depending on the eVect that
particular cleavage patterns exert in the mechanical prop-
erties of this lattice. Therefore, the characterization of
cleavage patterns in BM by diVerent SVMPs represents a
relevant task. Moreover, whether SVMPs are also able to
degrade BM components in vivo, and the extent of such
degradation, are issues that have not been thoroughly
investigated.
The presence of disintegrin-like and cysteine-rich
domains in P-III SVMPs has been postulated as playing a
critical role in their potent hemorrhagic activity [5]. Such
high hemorrhagic potential may be due, at least partially, to
the targeting of SVMPs to relevant locations in the capil-
lary wall, such as endothelial cell integrins [17], or through
the binding of exosites located in such additional domains
to speciWc sequences in BM and other extracellular matrix
components [18,19], thus contributing to a more localized,
speciWc and hence eYcient BM degradation. Thus, the anal-
ysis of the degradation patterns of BM substrates in vitro
and in vivo constitutes relevant issues to deepen our under-
standing of the mechanism of action of hemorrhagic
SVMPs.
In this work, a comparison has been performed between
two well-characterized hemorrhagic SVMPs: BaP1, a P-I
enzyme from Bothrops asper venom which has been consid-
ered as weakly hemorrhagic [20], and jararhagin, a P-III
enzyme from Bothrops jararaca venom which has a more
potent hemorrhagic activity [21]. The goals of this study
were to compare: (a) the turnover rate of these SVMPs on
azocasein; (b) the degradation patterns on BM components
incubated with these SVMPs in vitro; and (c) the ability of
these SVMPs to alter the immunostaining of BM compo-
nents of muscle capillaries in vivo.Materials and methods
Metalloproteinases
BaP1, a 22 kDa class P-I SVMP, was isolated from the venom of
B. asper [20,22]. Jararhagin, a 52 kDa class P-III SVMP, was isolated from
the venom of B. jararaca [21].
Degradation of azocasein
Proteolytic activity of BaP1 and jararhagin was tested on azocasein
(Sigma–Aldrich, St. Louis, MO) according to Wang et al. [23], with modiW-
cations. BrieXy, various concentrations of each SVMP, dissolved in 20 L
of 25 mM Tris, 150 mM NaCl, 5 mM CaCl2, pH 7.4, were incubated with a
5 mg/mL solution of azocasein in the same buVer. After an incubation of
90 min at 37 °C, the reaction was stopped by the addition of 200 L of 5%
trichloroacetic acid. Samples were then centrifuged at 2000 rpm. Superna-
tant (150 L) was diluted with 150 L 0.5 M NaOH, and the absorbances
were measured at 450 nm. One unit of proteolytic activity corresponds to
the amount of enzyme that induces a change in absorbance of 0.2.
Degradation of Matrigel
Hydrolysis of Matrigel ™ (BD Biosciences Discovery Labware, Bed-
ford, MA) was assessed by incubating this BM preparation with either
BaP1 or jararhagin at an enzyme:substrate ratio (w:w) of 1:50. Incubations
of SVMPs and Matrigel were performed for 15 min, 1 and 3 h at 37 °C.
Reactions were stopped by the addition of one volume of 2£ SDS–PAGE
buVer (reducing conditions) [24]. A sample of Matrigel, incubated without
SVMPs under otherwise identical conditions and at the same time inter-
vals, was used as control. Electrophoresis was performed using a 4–15%
Tris–HCl polyacrylamide gradient gel (Bio Rad Labs, Hercules, CA), and
the bands were visualized with Coomassie Brilliant Blue staining. For the
identiWcation of cleavage sites of Matrigel proteins, incubations with either
BaP1 or jararhagin were carried out as described for 1 h at 37 °C. After
SDS–PAGE in a 4–15% gradient gel, the samples were transferred to
immobilon strips and the bands visualized with Coomassie Brilliant Blue
Fig. 1. Hydrolytic activity of BaP1 () and jararhagin () on azocasein.
Various amounts of each enzyme were incubated with azocasein for
90 min at 37 °C, as described in Materials and Methods. Reaction was
stopped by the addition of 5% trichloroacetic acid, and the absorbances of
the supernatants at 450 nm were recorded. Controls of azocasein without
enzyme were run in parallel and their absorbance was subtracted from the
sample values. Results are presented as mean § SD (n D 3).
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Applied Biosystems Procise 494 protein sequencer instrument (following
the manufacturer’s recommendations).
Immunocytochemistry
Groups of CD-1 mice (18–20 g) were injected intramuscularly, in the
right gastrocnemius, with either saline solution (100 L control), BaP1
(30 g/100 L or 2 g/100 L), or jararhagin (5 g/100 L). Thirty micro-
grams of BaP1 and 5 g of jararhagin induced prominent hemorrhage in
the injected muscle; 2 g BaP1 did not induce hemorrhage and was
selected in order to compare the activity of BaP1 and jararhagin at the
same molar basis. At 15 min and 1 h after injection, mice were sacriWced
with an overdose of CO2 and the injected muscle was dissected out and
immediately placed in cold isopentane and frozen in liquid nitrogen. Sec-
tions of 8 m were cut in a cryotome (Leica CM 1850, Nussloch, Ger-
many) and Wxed in 100% ethanol. Sections were incubated with either anti-
mouse laminin polyclonal antibody (Research Diagnostics Inc., Concord,MA), at a 1:3000 dilution, anti-mouse type IV collagen polyclonal anti-
body (Research Diagnostics Inc.,) at a 1:3000 dilution, anti-mouse nidogen
polyclonal antibody (Chemicon) at a 1:8000 dilution, or anti-mouse vascu-
lar endothelial growth factor receptor 2 (VEGFR-2) monoclonal antibody
(BD Biosciences Pharmingen, San Diego, CA) at a 1:20 dilution. The reac-
tion was detected with the tyramide signal ampliWcation kit (Perkin Elmer,
Boston, MA) using biotinylated secondary antibodies. Visualization of
VEGFR-2 was performed with streptavidin-Xuorescein (DakoCytoma-
tion, Glostrup, Denmark) and BM antigens with streptavidin-Cy3 (Zymed
Laboratories Inc., South San Francisco, CA). Experiments involving mice
were approved by the Committee for the Use and Care of Laboratory Ani-
mals (CICUA) of the University of Costa Rica.
In order to have a quantitative assessment of capillary BM altera-
tions, sections from damaged areas were analyzed using the 20£ objec-
tive lens, and the total number of capillaries and muscle cells were
counted, in order to obtain the capillary:muscle cell ratio. This was pos-
sible since muscle Wbers can be identiWed on the basis of immunostaining
of their BM, which is less severely aVected than BM of capillaries and,Fig. 2. Hydrolysis of Matrigel proteins by BaP1 and jararhagin. (A) Matrigel was incubated with each enzyme at a 1:50 (w:w) enzyme:substrate ratio for
various time intervals. A control of Matrigel preparation incubated without enzymes was included at each time interval. Reactions were stopped by the
addition of SDS–PAGE reducing sample buVer, and mixtures separated by SDS–PAGE, run under reducing conditions, using a 4–15% polyacrylamide
gradient gel. Molecular mass markers were included (left lane). Gels were stained with Coomassie Brilliant Blue. In the controls, the most abundant Matri-
gel bands correspond to (1) Laminin -1 chain, (2) laminin  and  chains, (3) Nidogen chains. There is degradation of Matrigel components by the two
SVMPs as early as 15 min of incubation. (B) IdentiWcation of the cleavage sites of Matrigel components (laminin and nidogen chains) upon 1 h of incuba-
tion with BaP1 or jararhagin at a 1:50 (w:w) enzyme:substrate ratio. The molecular mass of degradation fragments is indicated, as well as their N-terminal
sequence. Samples were analyzed in triplicates. BaP1 generated cleavage fragments of both laminin and nidogen chains, whereas jararhagin generated
mostly fragments derived from nidogen.
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section, even in damaged areas. The capillary:muscle cell ratio is com-
monly used in the study of microvascular alterations in skeletal muscle
[25]. For these analyses, three to four sections were analyzed in each
sample for each BM antigen.
Statistical analysis
To assess the statistical signiWcance of the diVerences in the mean val-
ues of capillary:muscle cell ratios, an analysis of variance was performed,
followed by a Tukey–Kramer test to compare pairs of means.
Results
Degradation of azocasein and matrigel
BaP1 and jararhagin showed similar dose-response
curves of proteolytic activity when tested on azocasein
(Fig. 1). Activity was 500 and 400 U/mg for BaP1 and jar-
arhagin, respectively. However, in terms of molar basis, jar-
arhagin showed a higher activity than BaP1 (11 vs 21 U/
nmol), owing to the diVerent molecular mass of these
SVMPs. BaP1 and jararhagin were also tested for their abil-
ity to hydrolyze Matrigel. After 15 min of incubation, BaP1cleaved nidogen as well as laminin  and  chains, whereas
jararhagin predominantly degraded nidogen (Fig. 2A). At
1 h incubation with jararhagin, a reduction in the intensity
of laminin  chain was observed, although  and  chains
were apparently not degraded. Samples collected after 3 h
incubation show a complete degradation of the three bands
of laminin by BaP1, whereas jararhagin had completely
degraded laminin  chain; in addition, the band corre-
sponding to  and  laminin chains was reduced in intensity
(Fig. 2A). The N-terminal sequence of the main degrada-
tion fragments was determined after 1 h incubation of
Matrigel with BaP1 or jararhagin. As shown in Fig. 2B,
BaP1 generated fragments from the laminin  and  chains,
as well as of nidogen, whereas jararhagin predominantly
generated fragments derived from nidogen.
Immunocytochemistry
When sections of muscle tissue from mice injected with
saline solution were immunostained with anti-VEGFR-2, a
marker of endothelial cells, a typical distribution of capil-
lary blood vessels was evidenced (Fig. 3A). There were sev-
eral capillaries surrounding each muscle Wber in aFig. 3. Immunohistochemical staining for endothelial and BM markers in serial cryosections of skeletal muscle tissue (gastrocnemius) of control mice
15 min after injection of saline solution. The following primary antibodies were used: (A) anti-mouse vascular endothelial growth factor receptor 2
(VEGFR-2), (B) anti-mouse laminin, (C) anti-mouse nidogen, (D) anti-mouse type IV collagen. Reactions were detected with a tyramide signal ampliWca-
tion kit using biotinylated secondary antibodies. Visualization of VEGFR-2 was performed with streptavidin–Xuorescein, and BM antigens with strepta-
vidin-Cy3. Capillaries are clearly identiWed in the endomysium (arrow), and a continuous BM (arrow head) is observed in the periphery of skeletal muscle
Wbers (M). Bar represents 40 m.
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tissue [26]. A similar pattern was observed when sections
were incubated with anti-CD 31, another marker of endo-
thelial cells (not shown). Immunostaining of sections from
control mice with antibodies anti-type IV collagen, laminin
and nidogen revealed a staining pattern that was located in
capillary vessels and in the periphery of muscle Wbers
(Fig. 3B, C and D), corresponding to BMs of these two
structures.
Tissue injected with 30g BaP1 showed extensive areas
of hemorrhage, evidenced by the presence of extravasatederythrocytes located in the perimysium and endomysium in
samples collected at 15 min and 1 h after toxin injection, in
agreement with previous studies [14]. Staining for endothe-
lial cell markers was drastically reduced in the majority of
these hemorrhagic areas (Fig. 4A, C and E). In addition, the
patterns of immunostaining for the BM components lami-
nin (Fig. 4B), nidogen (Fig. 4D) and type IV collagen
(Fig. 4F) were altered in the capillary vessels of these areas,
with an evident reduction in the number of capillaries
stained for these antigens, as corroborated quantitatively
when the capillary:muscle cell ratio was determined in theseFig. 4. Immunohistochemical staining for endothelial and BM markers in serial cryosections of skeletal muscle tissue (gastrocnemius) of mice 15 min after
i.m. injection of 30 g BaP1. Sections correspond to areas showing evidences of tissue damage, i.e. hemorrhage. The following primary antibodies were
used: (A, C, E) anti-mouse vascular endothelial growth factor receptor 2 (VEGFR-2), (B) anti-mouse laminin, (D) anti-mouse nidogen, (F) anti-mouse
type IV collagen. Sections A and B, C and D, and E and F correspond to serial sections from the same tissue sample. Immunostaining was performed as
described in the legend of Fig. 3. There is a drastic reduction in the immunostaining of VEGFR-2 and BM markers in capillaries. There is a diVuse staining
in (A) and (C) that does not correspond to endothelial cells. BMs of skeletal muscle cells show some alterations, i.e. reduction in the intensity of immuno-
staining and interruption in their continuity (arrow), although such alterations were less pronounced that those observed in capillaries. Bar represents
40 m.
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BM markers in muscle Wbers was not as drastic as that
described for capillaries in severely aVected areas, and it
allowed the identiWcation of contour of muscle Wbers
(Fig. 4). Nevertheless, muscle BM showed a decrease in the
intensity of the Xuorescence, and there was interruption in
the continuity of the BM staining in some Wbers (Fig. 4).
These alterations in immunostaining for endothelial cells
and BM proteins were evident as early as 15 min after BaP1
injection, and a similar pattern was observed at 1 h. Hoechst
staining revealed an increment in the amount of nuclei in
BaP1-injected tissue, especially after 1 h of injection, but also
at 15 min (not shown). This increment probably corresponds
to leukocytes extravasated as a consequence of hemorrhage,
and also to the initial inXammatory inWltrate arriving to
damaged muscle. When 2g of BaP1 were injected, no mac-
roscopic hemorrhage developed in the muscle, and only a
local edema was observed, with increase in the area of inter-
stitial space. In these samples, the overall immunostaining
for endothelial cell markers and for BM proteins was not
reduced when compared with control samples (not shown).
Thus, in conditions where hemorrhage did not occur, there
was no evidence of loss of endothelial cell markers or capil-
lary basement membrane antigens.
As previously described [27], injection of 5g jararhagin
induced a prominent hemorrhagic response in gastrocne-
mius muscle, which was of a roughly similar extent to that
described above for 30 g BaP1. A similar immunocyto-
Fig. 5. Capillary:muscle cell ratios in mouse gastrocnemius cryosections
immunostained with anti-BM antigens. Muscles were injected with either
saline solution (open bars), 30 g BaP1 (bars with diagonally ascending
lines) or 5 g jararhagin (bars with diagonally descending lines). Tissue
samples were collected 15 min after injections and immunostaining was
performed as described in Materials and Methods. The total number of
capillaries and muscle cells were counted in various sections, and the cap-
illary:muscle cell ratio was calculated. Results are presented as mean § SD
(n D 4). *P < 0.05 when compared with capillary:muscle cell ratios of tis-
sue from mice injected with saline solution. No signiWcant diVerences
(P > 0.05) were observed neither between samples of tissue injected with
BaP1 and those injected with jararhagin nor between samples of a similar
treatment immunostained for the three BM antigens.
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*chemical pattern as the one described after injection of
30g BaP1 was observed, i.e. in areas of hemorrhage there
was a loss in the staining for the endothelial cell markers
and BM proteins in capillary vessels, whereas only a partial
reduction in immunostaining to BM proteins was observed
in skeletal muscle Wbers in aVected areas (Fig. 6). There was
a signiWcant drop in the capillary:muscle cell ratios in sec-
tions immunostained for the three BM antigens; such ratio
did not diVer from the ratio observed in sections of muscle
aVected by BaP1 (Fig. 5). Thus, the qualitative and quanti-
tative alterations in the immunostaining of BM proteins
laminin, type IV collagen and nidogen were similar when
hemorrhagic doses of BaP1 and jararhagin were injected
into muscle tissue. Moreover, the capillary:muscle cell ratio
calculated for tissue sections immunostained for diVerent
BM antigens did not show any signiWcant diVerence, either
when comparing BaP1 and jararhagin or when comparing
the three antigens among themselves (P > 0.05; Fig. 5). In
contrast, when these two SVMPs were compared on a simi-
lar molar basis, i.e. 5g jararhagin and 2g BaP1, the
former induced hemorrhage and a drastic loss of immuno-
staining to endothelial cells and BM proteins, whereas the
latter did not cause overt immunohistochemical alterations
and no hemorrhage, in agreement with the higher hemor-
rhagic activity of jararhagin.
Discussion
Since the early descriptions of SVMPs and SVMP-
induced hemorrhage, it has been postulated that a key step
in the pathogenesis of microvascular damage is the enzy-
matic hydrolysis of BM components [10,28]. However,
these observations were based primarily on in vitro degra-
dation studies. In general terms, P-III SVMPs display a
more potent hemorrhagic activity than P-I SVMPs. To
explain this diVerence, three possibilities have been postu-
lated: (a) P-III SVMPs may have a higher turnover rate on
the hydrolysis of BM components; (b) diVerent classes of
SVMPs may have a diVerent speciWcity concerning the sub-
strates which are predominantly hydrolyzed, with P-III
SVMPs having a higher activity on key BM components;
and (c) the presence of disintegrin-like and cysteine-rich
domains in P-III SVMPs may contribute to the targeting of
SVMPs to relevant sites in the microvasculature [3,5,7].
This targeting is likely to depend on the presence of exosites
to BM proteins or to the binding to endothelial cell inte-
grins, thus positioning these enzymes at sites where they are
able to degrade BM proteins and induce microvessel dis-
ruption more eYciently than P-I SVMPs, which lack these
additional exosite-containing domains. The role of these
additional domains has been recently supported by
structural and functional observations [19,29,30].
BaP1 and jararhagin showed a similar enzymatic activ-
ity, on a mass basis, on azocasein (400 U/mg for jararhagin
and 500 U/mg for BaP1). In contrast, the minimum hemor-
rhagic doses of these SVMPs are diVerent, being 5g for
jararhagin [31] and 20g for BaP1 [20]; therefore, the
150 T. Escalante et al. / Archives of Biochemistry and Biophysics 455 (2006) 144–153number of units of proteolytic activity in one minimum
hemorrhagic dose corresponds to 2 U for jararhagin and
10 U for BaP1. Thus, the striking diVerence in hemorrhagic
activity between these two proteinases cannot be explained
on the basis of enzymatic turnover rate alone. Our present
study also compared the patterns of degradation of Matri-
gel in vitro by these two SVMPs. The cleavage pattern on
laminin and nidogen induced by BaP1 was similar to the
one previously described for another class P-I SVMP, atrol-
ysin e, from the venom of C. atrox [12]. On the other hand,
jararhagin induced a somewhat diVerent degradationpattern when compared with BaP1, especially regarding
hydrolysis of laminin, which is slower and limited to the 
chain. Jararhagin generates predominantly nidogen-derived
fragments, which are similar to those described for the
action of atrolysin e [12].
The functional signiWcance of the diVerent patterns of
BM degradation by hemorrhagic SVMPs is a relevant
issue. BM plays a key role in the mechanical stability of
the capillary wall, providing resistance to the distention of
the capillary wall by the hemodynamic biophysical forces
normally operating in the circulation [32,33]. BM is aFig. 6. Immunohistochemical staining for endothelial and BM markers in serial cryosections of skeletal muscle tissue (gastrocnemius) of mice 15 min after
i.m. injection of 5 g jararhagin. Sections correspond to areas showing evidences of tissue damage, i.e. hemorrhage. The following primary antibodies were
used: (A, C, E) anti-mouse vascular endothelial growth factor receptor 2 (VEGFR-2), (B) anti-mouse laminin, (D) anti-mouse nidogen, (F) anti-mouse
type IV collagen. Sections A and B, C and D, and E and F correspond to serial sections from the same tissue sample. Immunostaining was performed as
described in the legend of Fig. 3. There is a drastic reduction in the immunostaining of VEGFR-2 and BM markers in capillaries. There is a diVuse staining
in (A) and (C) that does not correspond to endothelial cells. BMs of skeletal muscle cells show some alterations, i.e. reduction in the intensity of immuno-
staining and interruption in their continuity (arrow), although such alterations were less pronounced that those observed in capillaries. Bar represents
40 m.
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nantly laminin, type IV collagen and nidogen, together
with the proteoglycan perlecan [16]. The observed diVer-
ences in the cleavage sites of BaP1 and jararhagin on
nidogen might be of functional relevance. Nidogen is a
150 kDa protein comprising three globular domains
which mediate the interaction with various BM compo-
nents (Fig. 7) [34,35]. Domain G2 is involved in the inter-
action with type IV collagen and perlecan [35–37],
whereas domain G3 mediates the interaction with laminin
 chain [35,36,38,39]. Thus, nidogen plays a key role in the
networking of type IV collagen and laminin in BMs. It is
noteworthy that jararhagin cleaves nidogen at two sites,
between Ser 351 and Tyr 352, and between Thr 839 and
Leu 840, before the tyroglobulin-like repeat (Fig. 7). The
last cleavage would provoke the separation between the
molecular sites in nidogen that mediate the binding to
type IV collagen and laminin, an event that is likely to
promote a destabilization in the structure of nidogen,
jeopardizing its role as an integrator of type IV collagen
and laminin in BM (Fig. 7). In contrast, BaP1 cleaves
nidogen between Pro 335 and Gln 336, just before the G2
domain; such cleavage would not separate the regions in
nidogen responsible for interaction with type IV collagen
and laminin. This diVerence in the cleavage of nidogen
may contribute to the higher hemorrhagic activity of
jararhagin.
Immunohistochemical experiments demonstrated that
hemorrhagic SVMPs, at doses that induce hemorrhage,
cause a drastic loss in the immunostaining of both endothe-
lial cell markers and capillary BM components. In contrast,
injection of BaP1 at a non-hemorrhagic dose did not
provoke these alterations. This is the Wrst immunohisto-chemical demonstration of in vivo BM degradation by
snake venom hemorrhagic SVMPs. The loss of endothelial
cell markers evidences a drastic endothelial pathology, in
agreement with ultrastructural studies on the action of
hemorrhagic SVMPs showing prominent alterations, lead-
ing to endothelial cell disruption, that occur within minutes
of SVMP injection [40–42]. On the other hand, both quali-
tative and quantitative (i.e., capillary:muscle cell ratio)
assessments revealed a conspicuous reduction in the immu-
nostaining of BM antigens in capillaries upon treatment
with hemorrhagic doses of these SVMPs. It is noteworthy
that loss of immunostaining of BM antigens of capillaries
in hemorrhagic areas was similar for the three BM antigens,
thus suggesting an extensive loss in BM structure induced
by these SVMPs in vivo. Interestingly, the pattern of limited
proteolysis of BM proteins observed in vitro contrasts with
the prominent loss of immunostaining of these proteins in
aVected capillaries in vivo. It is unlikely that such limited
proteolytic proWle would eliminate all the epitopes recog-
nized by the polyclonal antibodies used in the immunohis-
tochemistry experiments.
These apparently contradictory observations may be
explained in the light of a hypothesis recently proposed to
explain the mechanism of action of hemorrhagic SVMPs
[7]. According to this model, capillary vessel disruption
occurs in two stages: initially, there is limited proteolysis
of BM proteins by SVMPs, as demonstrated in previous
studies (see Ref. 5 for a review) and in our in vitro obser-
vations. As a consequence, the mechanical stability of BM
is drastically weakened, and the hemodynamic biophysi-
cal forces normally operating in the circulation, i.e. wall
tension and shear stress, provoke a distention in the capil-
lary wall until its integrity is disrupted and extravasationFig. 7. Cleavage pattern of matrigel mouse nidogen in vitro by BaP1 and jararhagin. Cleavage sites were identiWed by N-terminal sequencing of the resul-
tant fragments separated by SDS–PAGE. The regions in nidogen responsible for interaction with type IV collagen, perlecan and laminin are shown. The
molecular organization of nidogen is based on [39], and the sequences of mouse nidogen were obtained from Swiss Prot data base (Accession No. P10493).
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hypothesis, it is suggested that such abrupt distention and
rupture results in the loss of integrity not only of endothe-
lial cells, but also of BM components, as observed at the
ultrastructural level [41,42]. In agreement with this
hypothesis, no evident ultrastructural changes occur in
the BM of capillaries in tissue injected with BaP1 when
blood Xow was abrogated [42]. In these circumstances, it is
likely that there is SVMP-induced limited proteolysis of
BM components, but the lack of blood Xow-dependent
enhanced wall tension precludes the mechanical disrup-
tion of BM structure.
In contrast to the prominent reduction of BM immu-
nostaining in capillaries where endothelial cells were dam-
aged, the eVects of hemorrhagic doses of BaP1 and
jararhagin in the immunostaining of components of BM
of skeletal muscle Wbers occurred to a more limited extent.
Despite subtle variations in the composition of BM in
capillaries and skeletal muscle Wbers [43], it is likely that
SVMPs induce a similar pattern of limited proteolysis in
their protein components. Nevertheless, the presence of
hemodynamic mechanical forces promoting distention in
capillaries, and the absence of similar forces in skeletal
muscle, would explain why there is a widespread loss of
BM immunostaining in aVected capillaries whereas only a
limited and partial loss occurs in BM surrounding muscle
cells.
In conclusion, our observations indicate that, when
injected at doses that provoke hemorrhage, both P-I and
P-III SVMPs induce prominent loss of BM components
in vivo, as judged by immunohistochemisty. Such drastic
loss of capillary BM antigens in vivo may depend on both
the limited enzymatic cleavage of BM components, and
the disruption caused by biophysical forces operating in
the microvasculature in vivo once BM stability has been
debilitated. In vitro observations revealed a partially
diVerent pattern of limited proteolysis induced by these
SVMPs on Matrigel. It remains to be determined whether
such diVerent hydrolytic patterns, as well as the higher
hemorrhagic activity of jararhagin over BaP1, depend on
diVerences in the metalloproteinase domain or on the
ability of disintegrin-like and cysteine-rich domains of jar-
arhagin to target it to speciWc sites in BM components of
capillary blood vessels.
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